Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antivirals/HIV Clear all
Completed Not applicable Interventional

The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

NCT00002312
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Not applicable Interventional

A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

NCT00002187
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Fomivirsen sodium
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 3 Interventional

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

NCT00002220
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Efavirenz, Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC

NCT00000753
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients

NCT00002326
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

NCT00071760
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GW433908, ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

NCT01950325
View directory record Official record
Conditions
HIV-1 Infection, Neutralizing Antibody, Monoclonal Antibody, Viral Load, HIV Antibodies
Interventions
VRC-HIVMAB060-00-AB
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

NCT00016718
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
90 Days to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

NCT00000791
View directory record Official record
Conditions
HIV Infections
Interventions
Glycovir, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

NCT00000691
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Not applicable Interventional

3TC (Lamivudine; GR109714X) Open-Label Program

NCT00002108
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 3 Interventional

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

NCT00234910
View directory record Official record
Conditions
HIV Infection
Interventions
Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Sep 28, 2026, 10:46 AM EDT
Completed No phase listed Observational

HCV/HIV Coinfection: Antiviral Therapy and Fibrosis

NCT01423643
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

NCT00121979
View directory record Official record
Conditions
HIV Infections
Interventions
Racivir, a non-nucleoside reverse transcriptase inhibitor
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Chicago, Illinois • The Bronx, New York • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

NCT00001082
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil, Adefovir dipivoxil placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 28, 2026, 10:46 AM EDT
Terminated Phase 4 Interventional

Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

NCT00234962
View directory record Official record
Conditions
HIV Infection
Interventions
Lopinavir/Ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2008 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

NCT00002210
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
1 Month to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:46 AM EDT
Completed No phase listed Observational

Clinical Outcomes of People Who Acquired HIV in Early Life

NCT01656564
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients

NCT00002198
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3

NCT00000747
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 3 Interventional

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

NCT00000841
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
85
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 28, 2026, 10:46 AM EDT
Withdrawn Phase 1 Interventional

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

NCT00003435
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, melphalan, antiviral therapy, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Duke University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

NCT00000760
View directory record Official record
Conditions
HIV Infections
Interventions
Ro 24-7429, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced Sep 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

NCT00000803
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 28, 2026, 10:46 AM EDT